Edwards Lifesciences (NYSE:EW) Stock Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Edwards Lifesciences Corporation NYSE: EW. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $50,001 and $100,000 in Edwards Lifesciences stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Edwards Lifesciences Trading Up 5.4%

Shares of NYSE:EW traded up $4.12 during trading on Friday, reaching $79.92. 15,656,685 shares of the stock were exchanged, compared to its average volume of 4,283,557. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences Corporation has a 12-month low of $59.41 and a 12-month high of $83.00. The firm has a market cap of $46.88 billion, a price-to-earnings ratio of 11.50, a price-to-earnings-growth ratio of 4.00 and a beta of 1.11. The firm's 50-day moving average price is $76.58 and its 200 day moving average price is $73.55.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter in the previous year, the business earned $0.70 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its position in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares during the period. Alyeska Investment Group L.P. acquired a new stake in Edwards Lifesciences in the fourth quarter worth $49,038,000. Dynamic Advisor Solutions LLC increased its position in Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after buying an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares during the period. Finally, Simplify Asset Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter worth $5,979,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Argus upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Stifel Nicolaus upped their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday. Piper Sandler upped their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday. Mizuho upped their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday. Finally, Canaccord Genuity Group upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $85.00.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 5,980 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the transaction, the chief executive officer directly owned 58,284 shares of the company's stock, valued at approximately $4,366,054.44. This trade represents a 9.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,848 shares of company stock valued at $2,314,488 over the last three months. 0.34% of the stock is currently owned by company insiders.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.